arrow
N

Nicholas C. Turner

Royal Marsden Hospital and Institute of Cancer Research
H指数:92
被引数:4.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

在激素受体阳性晚期乳腺癌一线治疗期间,于ESR1突变出现但疾病进展前转换至卡米泽斯特rant(SERENA-6):一项双盲、安慰剂对照、随机III期试验的扩展分析

2026-07-130
PRE
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer

腔内细胞系丢失驱动经治ER+ HER2−局部晚期或转移性乳腺癌对下一代ERα拮抗剂的耐药性

2026-04-010
OAAI
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature
IF48.5
2026-03-040
OAAI
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

SERENA-6试验中,卡米泽斯特ант联合CDK4/6抑制剂治疗在初次内分泌治疗期间出现ESR1突变的晚期乳腺癌患者的患者报告结局。

2025-10-200
OAAI
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis

英国乳腺癌患者全基因组数据与死亡率统计数据的关联:一项回顾性分析

2025-10-070
OAAI
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

安全性概述及inavolisib单药和联合疗法在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中的管理(GO39374)

2025-07-010
PRE
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Capivasertib 联合 Fulvestrant 治疗HR阳性/HER2阴性晚期乳腺癌:CAPItello-291研究扩展的中国队列

2025-05-090
OA
Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)

在 monarchE 试验中,ctDNA 检测在辅助阿贝西利联合内分泌治疗(ET)于 HR+/HER2-、淋巴结阳性、高危早期乳腺癌(EBC)中的预后价值

BREAST
IF7.9
2025-02-010
OAAI
Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial

monarchE试验中HR⁺、HER2⁻、淋巴结阳性、高危早期乳腺癌(EBC)患者原发肿瘤的基因组学和转录组学分析

BREAST
IF7.9
2025-02-010
OAAI
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer
2024-10-181
OAAI
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

CAPItello-291研究的简明语言摘要: 激素受体阳性的晚期乳腺癌中的Capivasertib

2024-09-162
OAAI
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Capivasertib和fulvestrant治疗激素受体阳性晚期乳腺癌患者: III期CAPItello-291研究中常见不良事件的特征、时程和处理

2024-09-013
OAAI
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

在ER阳性,HER2-negative晚期乳腺癌女性中,下一代口服SERD camizestrant的I期剂量递增和扩展试验: SERENA-1单药治疗结果

2024-08-016
OAAI
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
2024-07-260
OAAI
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
2024-05-141
PRE
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial
2024-05-021
PRE